The primary hyperoxaluria treatment market is growing due to the adoption of RNA interference therapies such as lumasiran, enzyme replacement candidates, and improved early genetic diagnosis. https://www.datamintelligence.com/research-report/primary-hyperoxaluria-treatment-market